Business
PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group
NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC,” “our,” or “we”) (Nasdaq: ELAB), a diversified holding
About this update from Pmgc Holdings Inc.
[{"type":"text","content":"NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC,” “our,” or “we”) (Nasdaq: ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group’s (“TCA”) Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-stage and seed-stage companies across all innovation-driven industries. Since its founding in 1997, TCA members have invested over $300 million in more than 525 companies, attracting an additional $2.2 billion in follow-on investments, primarily from venture capital firms. “We are excited to join forces with TCA Venture Group as a key sponsor,” said Graydon Bensler, CFA, Chief Executive Officer of PMGC. “This sponsorship aligns perfectly with our mission to identify and support high-potential companies, providing both capital and operational expertise to drive long-term growth. TCA’s vast network of investors, entrepreneurs, and industry experts will enhance our ability to expand our portfolio and execute our acquisition strategy while directly contributing to the thriving Southern California business ecosystem.” PMGC currently manages and operates a diverse portfolio of three wholly owned subsidiaries: NorthStrive Biosciences Inc. – A biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.PMGC Research Inc. – A research and development subsidiary, currently utilizing Canadian research grants and partnering with leading Canadian universities to accelerate scientific discovery and transform cutting-edge technologies into commercially viable products.PMGC Capital LLC. – A multi-strategy investment firm focused on direct investments, strategic lendi...